GB0123400D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0123400D0
GB0123400D0 GBGB0123400.4A GB0123400A GB0123400D0 GB 0123400 D0 GB0123400 D0 GB 0123400D0 GB 0123400 A GB0123400 A GB 0123400A GB 0123400 D0 GB0123400 D0 GB 0123400D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
silicon dioxide
colloidal silicon
disintegrant
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0123400.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9922916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0123400(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0123400.4A priority Critical patent/GB0123400D0/en
Publication of GB0123400D0 publication Critical patent/GB0123400D0/en
Priority to EC2002004323A priority patent/ECSP024323A/es
Priority to PE2002000948A priority patent/PE20030602A1/es
Priority to ARP020103642A priority patent/AR036643A1/es
Priority to DE60238131T priority patent/DE60238131D1/de
Priority to AT02774661T priority patent/ATE485813T1/de
Priority to DK02774661.9T priority patent/DK1432408T3/da
Priority to EP02774661A priority patent/EP1432408B8/en
Priority to HU0402394A priority patent/HU229991B1/hu
Priority to KR1020047004628A priority patent/KR100626785B1/ko
Priority to JP2003532038A priority patent/JP2005507897A/ja
Priority to SI200230928T priority patent/SI1432408T1/sl
Priority to BR0212922-1A priority patent/BR0212922A/pt
Priority to DK09177889.4T priority patent/DK2193788T3/en
Priority to PT02774661T priority patent/PT1432408E/pt
Priority to NZ531599A priority patent/NZ531599A/en
Priority to PT91778894T priority patent/PT2193788E/pt
Priority to CA2458455A priority patent/CA2458455C/en
Priority to MXPA04002814A priority patent/MXPA04002814A/es
Priority to NZ542273A priority patent/NZ542273A/en
Priority to HK04109968.5A priority patent/HK1067036B/en
Priority to US10/490,089 priority patent/US20040254210A1/en
Priority to EP09177889.4A priority patent/EP2193788B1/en
Priority to PL367896A priority patent/PL209704B1/pl
Priority to CO02087099A priority patent/CO5390072A1/es
Priority to PCT/EP2002/010890 priority patent/WO2003028705A1/en
Priority to CN2010101174089A priority patent/CN101912392A/zh
Priority to RU2004113205/15A priority patent/RU2322970C2/ru
Priority to CNA028190459A priority patent/CN1561201A/zh
Priority to IL16049802A priority patent/IL160498A0/xx
Priority to ES02774661T priority patent/ES2354687T3/es
Priority to BRPI0212922-1A priority patent/BRPI0212922B1/pt
Priority to MYPI20023631A priority patent/MY150060A/en
Priority to TW091122345A priority patent/TWI242449B/zh
Priority to CN2006101159063A priority patent/CN1951390B/zh
Priority to ES09177889.4T priority patent/ES2560106T3/es
Priority to ZA200401300A priority patent/ZA200401300B/en
Priority to IL160498A priority patent/IL160498A/en
Priority to NO20041270A priority patent/NO333892B1/no
Priority to HK10107727.3A priority patent/HK1141239B/en
Priority to JP2008309431A priority patent/JP5160386B2/ja
Priority to US12/776,711 priority patent/US20100221331A1/en
Priority to CY20101101091T priority patent/CY1111119T1/el
Priority to US13/158,921 priority patent/US20110306630A1/en
Priority to US13/489,396 priority patent/US8617598B2/en
Priority to ARP140103055A priority patent/AR097341A2/es
Priority to CY20161100068T priority patent/CY1117164T1/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
GBGB0123400.4A 2001-09-28 2001-09-28 Organic compounds Ceased GB0123400D0 (en)

Priority Applications (47)

Application Number Priority Date Filing Date Title
GBGB0123400.4A GB0123400D0 (en) 2001-09-28 2001-09-28 Organic compounds
EC2002004323A ECSP024323A (es) 2001-09-28 2002-09-26 Compuestos organicos
PE2002000948A PE20030602A1 (es) 2001-09-28 2002-09-26 Composicion farmaceutica que comprende un macrolido
ARP020103642A AR036643A1 (es) 2001-09-28 2002-09-26 Compuestos organicos
DE60238131T DE60238131D1 (de) 2001-09-28 2002-09-27 Pharmazeutische zubereitungen enthaltend kolloidales siliciumdioxid
AT02774661T ATE485813T1 (de) 2001-09-28 2002-09-27 Pharmazeutische zubereitungen enthaltend kolloidales siliciumdioxid
DK02774661.9T DK1432408T3 (da) 2001-09-28 2002-09-27 Farmaceutiske sammensætninger indeholdende kolloidt siliciumdioxid
EP02774661A EP1432408B8 (en) 2001-09-28 2002-09-27 Pharmaceutical compositions comprising colloidal silicon dioxide
HU0402394A HU229991B1 (en) 2001-09-28 2002-09-27 Pharmaceutical compositions comprising colloidal silicon dioxide
KR1020047004628A KR100626785B1 (ko) 2001-09-28 2002-09-27 콜로이드성 이산화규소를 포함하는 제약 조성물
JP2003532038A JP2005507897A (ja) 2001-09-28 2002-09-27 コロイド状二酸化ケイ素を含んでなる医薬組成物
SI200230928T SI1432408T1 (sl) 2001-09-28 2002-09-27 Farmacevtski sestavki, ki obsegajo koloidni silicijev dioksid
BR0212922-1A BR0212922A (pt) 2001-09-28 2002-09-27 Composições farmacêuticas
DK09177889.4T DK2193788T3 (en) 2001-09-28 2002-09-27 Pharmaceutical compositions comprising colloidal silicon dioxide
PT02774661T PT1432408E (pt) 2001-09-28 2002-09-27 Composições farmacêuticas que compreendem dióxido de silício coloidal
NZ531599A NZ531599A (en) 2001-09-28 2002-09-27 Pharmaceutical compositions that dissolve rapidly comprising a macrolide solid, a disintegrant and 1 to 5% of a colloidal silicon dioxide by weight
PT91778894T PT2193788E (pt) 2001-09-28 2002-09-27 Composições farmacêuticas compreendendo dióxido de silício coloidal
CA2458455A CA2458455C (en) 2001-09-28 2002-09-27 Pharmaceutical compositions comprising colloidal silicon dioxide
MXPA04002814A MXPA04002814A (es) 2001-09-28 2002-09-27 Composiciones farmaceuticas que comprenden dioxido de silicio coloidal.
NZ542273A NZ542273A (en) 2001-09-28 2002-09-27 Use of a pharmaceutical composition comprising collodial silicon dioxide
HK04109968.5A HK1067036B (en) 2001-09-28 2002-09-27 Pharmaceutical compositions comprising colloidal silicon dioxide
US10/490,089 US20040254210A1 (en) 2001-09-28 2002-09-27 Pharmaceutical compositions comprising colloidal silicon dioxide
EP09177889.4A EP2193788B1 (en) 2001-09-28 2002-09-27 Pharmaceutical compositions comprising colloidal silicon dioxide
PL367896A PL209704B1 (pl) 2001-09-28 2002-09-27 Kompozycja farmaceutyczna w postaci tabletki do sporządzania zawiesin oraz sposób wytwarzania tabletki do sporządzania zawiesin zawierającej 40-O-(2-hydroksy)etylo-rapamycynę
CO02087099A CO5390072A1 (es) 2001-09-28 2002-09-27 Compuestos organicos
PCT/EP2002/010890 WO2003028705A1 (en) 2001-09-28 2002-09-27 Pharmaceutical compositions comprising colloidal silicon dioxide
CN2010101174089A CN101912392A (zh) 2001-09-28 2002-09-27 包含胶态二氧化硅的药物组合物
RU2004113205/15A RU2322970C2 (ru) 2001-09-28 2002-09-27 Фармацевтические композиции, включающие коллоидную двуокись кремния
CNA028190459A CN1561201A (zh) 2001-09-28 2002-09-27 包含胶态二氧化硅的药物组合物
IL16049802A IL160498A0 (en) 2001-09-28 2002-09-27 Pharmaceutical compositions comprising colloidal silicon dioxide
ES02774661T ES2354687T3 (es) 2001-09-28 2002-09-27 Composiciones farmacéuticas que contienen dióxido de silicio coloidal.
BRPI0212922-1A BRPI0212922B1 (pt) 2001-09-28 2002-09-27 Composição farmacêutica na forma de um comprimido dispersável compreendendo uma dispersão sólida de 40-o-(2-hidroxietil)-rapamicina, seu processo de preparação e uso da dita composição
MYPI20023631A MY150060A (en) 2001-09-28 2002-09-27 Pharmaceutical compositions comprising colloidal silicon dioxide
TW091122345A TWI242449B (en) 2001-09-28 2002-09-27 Pharmaceutical compositions
CN2006101159063A CN1951390B (zh) 2001-09-28 2002-09-27 包含胶态二氧化硅的药物组合物
ES09177889.4T ES2560106T3 (es) 2001-09-28 2002-09-27 Composiciones farmacéuticas que comprenden dióxido de silicio coloidal
ZA200401300A ZA200401300B (en) 2001-09-28 2004-02-18 Pharmaceutical compositions comprising colloidal silicon dioxide.
IL160498A IL160498A (en) 2001-09-28 2004-02-19 Pharmaceutical compositions in the form of dispersible tablet comprising a solid dispersion of rapamycin or ascomycin, a disintegrant and colloidal silicon dioxide and process for producing said tablet
NO20041270A NO333892B1 (no) 2001-09-28 2004-03-26 Farmasøytiske sammensetninger som innbefatter kolloid silikondioksid
HK10107727.3A HK1141239B (en) 2001-09-28 2004-12-15 Pharmaceutical compositions comprising colloidal silicon dioxide
JP2008309431A JP5160386B2 (ja) 2001-09-28 2008-12-04 コロイド状二酸化ケイ素を含んでなる医薬組成物
US12/776,711 US20100221331A1 (en) 2001-09-28 2010-05-10 Pharmaceutical compositions comprising colloidal silicon dioxide
CY20101101091T CY1111119T1 (el) 2001-09-28 2010-11-30 Φαρμακευτικα σκευασματα που περιλαμβανουν κολλοειδες διοξειδιο του πυριτιου
US13/158,921 US20110306630A1 (en) 2001-09-28 2011-06-13 Pharmaceutical compositions comprising colloidal silicon dioxide
US13/489,396 US8617598B2 (en) 2001-09-28 2012-06-05 Pharmaceutical compositions comprising colloidal silicon dioxide
ARP140103055A AR097341A2 (es) 2001-09-28 2014-08-14 Composición farmaceutica que comprende una dispersión de macrólidos sólidos, y un proceso para producir una tableta dispersable que contiene un macrólido
CY20161100068T CY1117164T1 (el) 2001-09-28 2016-01-21 Φαρμακευτικες συνθεσεις περιλαμβανουσες κολλοειδες διοξειδιο πυριτιου

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0123400.4A GB0123400D0 (en) 2001-09-28 2001-09-28 Organic compounds

Publications (1)

Publication Number Publication Date
GB0123400D0 true GB0123400D0 (en) 2001-11-21

Family

ID=9922916

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0123400.4A Ceased GB0123400D0 (en) 2001-09-28 2001-09-28 Organic compounds

Country Status (30)

Country Link
US (4) US20040254210A1 (https=)
EP (2) EP1432408B8 (https=)
JP (2) JP2005507897A (https=)
KR (1) KR100626785B1 (https=)
CN (3) CN1561201A (https=)
AR (2) AR036643A1 (https=)
AT (1) ATE485813T1 (https=)
BR (2) BR0212922A (https=)
CA (1) CA2458455C (https=)
CO (1) CO5390072A1 (https=)
CY (2) CY1111119T1 (https=)
DE (1) DE60238131D1 (https=)
DK (2) DK2193788T3 (https=)
EC (1) ECSP024323A (https=)
ES (2) ES2354687T3 (https=)
GB (1) GB0123400D0 (https=)
HU (1) HU229991B1 (https=)
IL (2) IL160498A0 (https=)
MX (1) MXPA04002814A (https=)
MY (1) MY150060A (https=)
NO (1) NO333892B1 (https=)
NZ (2) NZ531599A (https=)
PE (1) PE20030602A1 (https=)
PL (1) PL209704B1 (https=)
PT (2) PT1432408E (https=)
RU (1) RU2322970C2 (https=)
SI (1) SI1432408T1 (https=)
TW (1) TWI242449B (https=)
WO (1) WO2003028705A1 (https=)
ZA (1) ZA200401300B (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
PT1478648E (pt) 2002-02-01 2014-07-15 Ariad Pharma Inc Compostos contendo fósforo e suas utilizações
AU2003272489B2 (en) * 2002-09-17 2008-11-13 Wyeth Granulated formulation of the rapamycin ester CCI779
JPWO2004035089A1 (ja) * 2002-10-09 2006-02-09 協和醗酵工業株式会社 ホルモン依存性癌の治療剤
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
PL1901773T3 (pl) * 2005-06-09 2012-09-28 Hansa Medical Ab Zastosowanie proteinazy IDES (Z S. Pyogenes) do leczenia chorób autoimmunologicznych oraz odrzutów przeszczepu
JP2010509400A (ja) * 2006-11-14 2010-03-25 アリアド・ファーマシューティカルズ・インコーポレイテッド 経口処方組成物
MX2009008935A (es) 2007-02-23 2009-11-02 Gilead Sciences Inc Moduladores de las propiedades farmacocineticas de productos terapeuticos.
MX2010011963A (es) 2008-05-02 2010-12-06 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
CN101439025B (zh) * 2008-12-31 2011-05-11 江苏大学 一种水飞蓟素高效长效制剂及其制法
CN101444503B (zh) * 2008-12-31 2011-02-02 江苏大学 一种水飞蓟宾高效长效制剂及其制法
CN101444494B (zh) * 2008-12-31 2011-03-30 江苏大学 难溶性药物高效长效缓释制剂及其制法
JP5643227B2 (ja) * 2009-01-21 2014-12-17 マイラン インコーポレイテッドＭｙｌａｎ Ｉｎｃ． 炭酸ランタンの崩壊製剤
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI471321B (zh) * 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
US8927009B2 (en) 2009-12-22 2015-01-06 Abbvie Inc. ABT-263 capsule
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US20120045433A1 (en) * 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
CA3152557A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
ES2603129T3 (es) 2010-11-23 2017-02-23 Abbvie Ireland Unlimited Company Métodos de tratamiento utilizando inhibidores selectivos de Bcl-2
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
DE102011052396A1 (de) * 2011-08-04 2013-02-07 Gelita Ag Verfahren zur Herstellung einer stabilen Dispersion von Nanopartikeln, hergestellte Dispersion und deren Verwendung
KR101151890B1 (ko) * 2011-08-11 2012-05-31 동아제약주식회사 안정화 및 가용화된 시롤리무스 유도체 조성물의 제조방법
ES2663744T3 (es) 2011-10-06 2018-04-16 Novartis Ag Composiciones farmacéuticas que comprenden 40-O-(2-hidroxi)etil-rapamicina
CN102793673A (zh) * 2012-09-07 2012-11-28 中国药科大学 一种小檗碱磷脂复合物固体分散体及其制备方法
AU2014209141B2 (en) 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TW201503912A (zh) * 2013-03-19 2015-02-01 Novartis Ag 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物
AU2014348657A1 (en) 2013-11-13 2016-05-19 Novartis Ag mTOR inhibitors for enhancing the immune response
CN103610646B (zh) * 2013-12-05 2015-07-15 江苏奥赛康药业股份有限公司 一种含依维莫司的组合物及其制备方法和含有这一组合物的药物制剂
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
WO2016135740A1 (en) 2015-02-23 2016-09-01 Natco Pharma Limited Process for preparing stable oral compositions of everolimus
CA2986359A1 (en) 2015-05-20 2016-11-24 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
EP3329916A4 (en) 2015-07-28 2019-03-20 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF, AND PROCESS FOR PRODUCING THE SAME
WO2017204215A1 (ja) 2016-05-27 2017-11-30 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
JP7027412B2 (ja) 2016-09-30 2022-03-01 サリックス ファーマスーティカルズ，インコーポレーテッド リファキシミンの固体分散体の形態
CN110114070A (zh) 2016-11-23 2019-08-09 诺华公司 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
EP3565520B1 (en) 2017-01-06 2026-02-25 Palvella Therapeutics, Inc. Anhydrous compositions of mtor inhibitors and methods of use
JP2019529343A (ja) 2017-07-05 2019-10-17 ノバルティス アーゲー 新規な医薬組成物
CN108125918B (zh) * 2018-01-12 2020-06-23 杭州中美华东制药有限公司 依维莫司药物组合物
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
CN115666516A (zh) * 2020-06-01 2023-01-31 希尔帕医疗保健有限公司 包括卡培他滨的快速分散药物组合物
JP7825575B2 (ja) 2020-06-26 2026-03-06 バウシュ ヘルス アイルランド リミテッド 標的化放出リファキシミン組成物
WO2022219652A1 (en) * 2021-04-17 2022-10-20 Bdr Pharmaceuticals International Private Limited Novel sublingual pharmaceutical formulations for everolimus
CN119523923A (zh) * 2024-11-21 2025-02-28 华中药业股份有限公司 一种左炔诺孕酮片及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
US5211958A (en) * 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
US4920102A (en) * 1988-04-18 1990-04-24 Eli Lilly And Company Method for treating gastrointestinal disorders
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
CA2110166C (en) 1991-07-03 2002-11-05 Robert Wu-Wei Shen Tableting of colestipol hydrochloride
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
IL129547A (en) 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
DE19544507B4 (de) 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
ATE216887T1 (de) * 1996-02-29 2002-05-15 Fujisawa Pharmaceutical Co Beta-lactam-antibiotikum enthaltende tabletten und verfahren zu deren herstellung
JP4064476B2 (ja) 1996-03-29 2008-03-19 エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド 二酸化珪素を有する球状凝集した澱粉
EP0906754B1 (en) * 1996-04-26 2002-12-11 Shionogi & Co., Ltd. Rapid-release s1452 tablets
GB2318511A (en) * 1996-10-23 1998-04-29 Eurand Int Process for the preparation of a pharmaceutical composition for rapid suspension in water
CA2271652A1 (en) 1996-11-12 1998-05-22 Pharmacia & Upjohn Ab Compact member comprising a plurality of porous cellulose matrices, (pcms), method of manufacturing and use thereof
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US6080427A (en) * 1997-04-17 2000-06-27 Bristol-Myers Squibb Company Cefadroxil monohydrate tablet formulation
CA2293793C (en) 1997-06-13 2006-07-11 American Home Products Corporation Rapamycin formulations for oral administration
ME00189B (me) 1998-03-26 2011-02-10 Astellas Pharma Inc Preparati sa neprekidnim oslobađanjem
FR2785538B1 (fr) * 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
GB9826656D0 (en) * 1998-12-03 1999-01-27 Novartis Ag Organic compounds
WO2000054752A1 (fr) * 1999-03-15 2000-09-21 Kaken Pharmaceutical Co., Ltd. Comprimes a delitement rapide et procede de fabrication
FR2793690B1 (fr) 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
WO2000071117A1 (en) * 1999-05-21 2000-11-30 Kissei Pharmaceutical Co., Ltd. Immediate release medicinal compositions for oral use
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
WO2003030868A1 (en) 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
KR20070094666A (ko) 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
TWI347942B (en) 2005-06-22 2011-09-01 Lundbeck & Co As H Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base

Also Published As

Publication number Publication date
NO20041270L (no) 2004-06-14
HK1067036A1 (en) 2005-04-01
US20100221331A1 (en) 2010-09-02
RU2004113205A (ru) 2005-04-20
NO333892B1 (no) 2013-10-14
NO20041270D0 (no) 2004-03-26
RU2322970C2 (ru) 2008-04-27
HUP0402394A2 (hu) 2005-09-28
IL160498A (en) 2011-07-31
NZ542273A (en) 2007-11-30
DK2193788T3 (en) 2016-02-01
ES2560106T3 (es) 2016-02-17
EP1432408B1 (en) 2010-10-27
ES2354687T3 (es) 2011-03-17
EP1432408A1 (en) 2004-06-30
CY1111119T1 (el) 2015-06-11
EP2193788A1 (en) 2010-06-09
US20120289536A1 (en) 2012-11-15
DE60238131D1 (de) 2010-12-09
CA2458455C (en) 2011-07-12
EP2193788B1 (en) 2015-10-21
EP1432408B8 (en) 2011-03-02
DK1432408T3 (da) 2011-02-07
PL209704B1 (pl) 2011-10-31
TWI242449B (en) 2005-11-01
HK1141239A1 (en) 2010-11-05
HU229991B1 (en) 2015-04-28
ZA200401300B (en) 2004-10-27
CN1951390B (zh) 2010-11-03
US20110306630A1 (en) 2011-12-15
AR036643A1 (es) 2004-09-22
JP5160386B2 (ja) 2013-03-13
PT1432408E (pt) 2010-12-07
JP2009102341A (ja) 2009-05-14
CA2458455A1 (en) 2003-04-10
HUP0402394A3 (en) 2005-12-28
US20040254210A1 (en) 2004-12-16
BRPI0212922B1 (pt) 2018-03-13
AR097341A2 (es) 2016-03-09
PL367896A1 (en) 2005-03-07
CN101912392A (zh) 2010-12-15
PT2193788E (pt) 2016-02-23
BR0212922A (pt) 2004-10-13
IL160498A0 (en) 2004-07-25
US8617598B2 (en) 2013-12-31
CY1117164T1 (el) 2017-04-05
WO2003028705A1 (en) 2003-04-10
CN1561201A (zh) 2005-01-05
CN1951390A (zh) 2007-04-25
KR20040037197A (ko) 2004-05-04
ECSP024323A (es) 2003-04-25
NZ531599A (en) 2005-12-23
MXPA04002814A (es) 2004-07-05
JP2005507897A (ja) 2005-03-24
MY150060A (en) 2013-11-29
CO5390072A1 (es) 2004-04-30
KR100626785B1 (ko) 2006-09-21
SI1432408T1 (sl) 2011-02-28
ATE485813T1 (de) 2010-11-15
PE20030602A1 (es) 2003-08-27

Similar Documents

Publication Publication Date Title
GB0123400D0 (en) Organic compounds
GB0128996D0 (en) Organic compounds
IL160708A0 (en) 1, 6-naphthyridine derivatives as antidiabetics
PL370041A1 (en) 2,4-disubstituted pyrimidinyl derivatives for use as anticancer agents
EP1399414A4 (en) SUBSTITUTED TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF MALARIA
IL160081A0 (en) Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
PT1975164E (pt) Compostos de octa-hidrobenzimidazolona utilizados como analgésicos
WO2003041664A1 (fr) Cosmetiques contenant un mineral argileux
MXPA02004017A (es) Composiciones inorganicas/organicas.
MXPA03004980A (es) Delta 1-pirrolinas usadas como pesticidas.
PL367179A1 (en) 3,7-diazabicyclo [3.3.1] formulations as antiarhythmic compounds
AU2002309038A1 (en) Compositions for transmucosal administration containing coenzyme Q as the active ingredient
MXPA03009315A (es) 1.3-dionas carbociclicas tiazolil-substituidas como agentes pesticidas.
IL162310A0 (en) 3,4-Dihydro-1h-isoquinoloin-2-yl-derivatives
NO20034529D0 (no) 3,7-diazabicyklo(3,3,1) formuleringer samt antiarytmiforbindelser
IL158035A0 (en) 3, 7-diazabicyclo [3.3.1] formulations as antiarrhythmic compounds
AU2002367109A1 (en) Novel crystalline tricyclic triazolobenzazepine derivative
AU2002249561A1 (en) Novel substituted 1,2,4-trioxanes useful as antimalarial agents and a process for the preparation thereof
EP2116552A3 (en) Peptides, derivatives thereof, process for producing the same, strain producing the same, and antiviral agent comprising the same as active ingredient
PT1497256E (pt) Compostos de 1,5-diaminopentan-3-ol substituídos
DE60237360D1 (en) Glycopeptidantibiotika
SI1389213T1 (sl) 3,7-diazabiciklo(3.3.1)formulacije kot antiaritmicne spojine
GB0111071D0 (en) Disubstituted 1, 7-guanines
AU2002312214A1 (en) Organic/inorganic nanocomposites obtained by extrusion
AU2002233637A1 (en) Medicinal composition containing 1,3-thiazine derivative

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)